PharmaLogic Holdings Corp. has entered into an agreement to acquire the Contract Development and Manufacturing Organisation (CDMO) business and Springfield manufacturing facility in New Jersey, USA, from Lantheus Holdings, Inc. Financial details of the transaction have not been disclosed.
Key highlights of the acquisition:
🔹 Strategic Expansion: The acquisition will strengthen PharmaLogic’s US manufacturing capabilities in radiopharmaceutical therapeutics.
🔹 Advanced Manufacturing: The Springfield facility specialises in radiopharmaceuticals, with expertise in theranostics, research and clinical development.
🔹 Integration with Agilera: Following completion, the facility’s team will join Agilera, PharmaLogic’s therapeutic CDMO business.
🔹 Long-Term Partnership: Agilera will manufacture lutetium Lu 177 dotatate for Lantheus under a long-term supply agreement.
🔹 Global RLT Platform: The deal aims to establish a transatlantic CDMO platform supporting radioligand therapies (RLTs) from early-stage clinical development to commercial launch and global supply.
Agilera brings more than 15 years of experience in RLT development and commercialisation and currently supplies an alpha therapy to over 30 countries.
According to Etienne Montagut, President and CEO of PharmaLogic, the acquisition will strengthen Agilera’s specialised radioligand therapy capabilities while significantly expanding its US manufacturing capacity.
The transaction remains subject to regulatory approvals and customary closing conditions. Both businesses will continue operating independently until completion.
Industry Perspective: This acquisition highlights the growing strategic importance of radiopharmaceuticals and radioligand therapies in the global pharmaceutical manufacturing ecosystem, reinforcing investment in specialised CDMO infrastructure and advanced cancer treatments.
#PharmaLogic #Lantheus #Pharmaceuticals #CDMO #Radiopharmaceuticals #RadioligandTherapy #Healthcare #PharmaManufacturing #Biotechnology #USManufacturing #Investment